-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Venus A-Plus is China's first approved recyclable catheter aortic valve replacement system, adding recyclable, repositionable functionality to its advantages of retaining the strong radial support of the first generation Ofus A-Valve valve system.
of Veneus A-Plus marks the beginning of a "recyclable era" for China's original artificial valve system.
chinese aortic valve stenosis patients have a high proportion of dile leaf valve malformations, such patients usually show the characteristics of calcified weight, asymmetry, combined aortic disease, etc. , the operation is more difficult.
VenusA-Plus optimizes surgical operation, improves surgical success rate and safety, and is expected to significantly accelerate the promotion and technology of catheterized artificial aortic valve replacement ("TAVR") in China.
VenusA-Plus Registered Clinical Trials were conducted by Professor Wang Jian'an of the Second Hospital affiliated with Zhejiang University School of Medicine, with the participation of Sun Yat-sen Hospital affiliated with Fudan University, Yan foreign hospital of the Chinese Academy of Medical Sciences and Huaxi Hospital of Sichuan University.
Compared to The Venus A-Valve valve system, the Venus A-Plus valve system demonstrates better safety, with a compound endpoint event rate below the pre-set target boundary, demonstrating the product's good clinical safety, effectiveness and handling.
note: There are deletions in the original text